[1] Pezzutto A, Rabinovitch PS,et al. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin [J]. J Immunol. 1988, 140:1791–1795. [2] Wilson GL, Fox CH,et al. cDNA cloning of the B cellmembrane protein CD22: amediator of B-B cell interactions [J...
The Pan-B Cell Marker CD22 (siglec 2) Is Expressed On Gastro-intestinal (GI) Eosinophils And Negatively Regulates GI Eosinophil SurvivalEPEC TirITIMSHP1/2cytokinesmacrophagesAcute anaphylaxis (AAN) is rare in children and is difficult to diagnose especially in cases of inaugural manifestation. A ...
背景 接受CD19 CAR-T细胞疗法(CAR19)后发生进展的复发/难治性大B细胞淋巴瘤(LBCL)患者预后不佳。CD22表达于大多数B细胞淋巴瘤。本文报告了靶向CD22 (CAR22)的自体CAR-T细胞疗法用于治疗CAR19治疗后复发的R/R LBCL成人患者的效...
However, CD22−/− splenic B cells expressed twice as many major histocompatibility complex (MHC) class II molecules (data not shown), but had normal levels of the pan B-cell marker CD19, of the adhesion molecules CD24, VLA-4 and LFA-1, and of the activation markers CD69, B7.1 ...
接受CD19 CAR-T细胞疗法(CAR19)后发生进展的复发/难治性大B细胞淋巴瘤(LBCL)患者预后不佳。CD22表达于大多数B细胞淋巴瘤。本文报告了靶向CD22 (CAR22)的自体CAR-T细胞疗法用于治疗CAR19治疗后复发的R/R LBCL成人患者的效果。...
N = 5 G Effect of suciraslimab on α4 integrin surface expression on T cell of human PBMC. One-way ANOVA, F = 0.7059, P = 0.5131. N = 5. H Effect of suciraslimab on α4 integrin surface expression on B cell of human PBMC. One-way ANOVA, F = 66.02,...
上海玉博生物科技有限公司 主要致力于“PIERCEMA123664Anti-CD22 B-cell Monoclonal Antibody500 µl3741 500 µl”的生产销售。多年的“PIERCEMA123664Anti-CD22 B-cell Monoclonal Antibody500 µl3741 500 µl”生产与销售的经验,与各行业新老用户建立了稳定的
| bindingsite | binitio | bio express | Bio Plas Inc. | Bio World | bio x cell | bioabb | bioacademia | bioassay | bioassay systems | bioassay works | bioaustralis | biobasic | biocare | biocare medical | biocarta | biocat | biocatalysts | biocell | biochain | biocheck | Biochrom ...
CD22, an inhibitory receptor on B cells, modulates peripheral immune response towards self-antigen [10]. CD22 regulates B cell activation via recognition of NeuAcα2–6Galβ1–4GlcNAc (α2,6-linked sialic acid) with its sialic acid binding domain (Domain 1 of CD22 extracellular domain) [...
Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-AL